Division of Cardiology, Department of Medicine (N.A., M.G., T.T., A.A., M.T.C., A.L.), Mayo Clinic, Rochester, MN.
Division of Hematology-Oncology, Department of Medicine (T.L., J.F., Z.X., C.F., M.M.P.), Mayo Clinic, Rochester, MN.
Arterioscler Thromb Vasc Biol. 2023 May;43(5):774-783. doi: 10.1161/ATVBAHA.122.318928. Epub 2023 Mar 23.
Clonal hematopoiesis (CH) of indeterminate potential (CHIP) is a risk factor for cardiovascular disease. The relationship between CHIP and coronary microvascular dysfunction (CMD) is unknown. The current study examines the association between CHIP and CH with CMD and the potential relationships in risk for adverse cardiovascular outcomes.
In this retrospective observational study, targeted next-generation sequencing was performed for 177 participants with no coronary artery disease who presented with chest pain and underwent routine coronary functional angiogram. Patients with somatic mutations in leukemia-associated driver genes in hematopoietic stem and progenitor cells were examined; CHIP was considered at a variant allele fraction ≥2%; CH was considered at a variant allele fraction ≥1%. CMD was defined as coronary flow reserve to intracoronary adenosine of ≤2. Major adverse cardiovascular events considered were myocardial infarction, coronary revascularization, or stroke.
A total of 177 participants were examined. Mean follow-up was 12±7 years. A total of 17 patients had CHIP and 28 had CH. Cases with CMD (n=19) were compared with controls with no CMD (n=158). Cases were 56±9 years, were 68% women, and had more CHIP (27%; =0.028) and CH (42%; =0.001) than controls. CMD was associated with independent risk for major adverse cardiovascular events (hazard ratio, 3.89 [95% CI, 1.21-12.56]; =0.023), and 32% of this risk was mediated by CH. The risk mediated by CH was ≈0.5× as large as the direct effect of CMD on major adverse cardiovascular events.
In humans, we observe patients with CMD are more likely to have CHIP, and nearly one-third of major adverse cardiovascular events in CMD are mediated by CH.
不确定潜能的克隆性造血(CH)是心血管疾病的一个危险因素。CH 与冠状动脉微血管功能障碍(CMD)之间的关系尚不清楚。本研究旨在探讨 CH 与伴有 CMD 的 CH 之间的相关性,以及与不良心血管结局风险的潜在关系。
本回顾性观察性研究对 177 名因胸痛而行常规冠状动脉功能血管造影且无冠状动脉疾病的患者进行了靶向二代测序。检查了造血干细胞和祖细胞中存在与白血病相关驱动基因突变的患者;CH 被定义为等位基因变异分数≥1%;CHIP 被定义为等位基因变异分数≥2%。CMD 定义为冠状动脉内腺苷引起的冠状动脉血流储备≤2。考虑的主要不良心血管事件为心肌梗死、冠状动脉血运重建或中风。
共检查了 177 名患者。平均随访时间为 12±7 年。共有 17 名患者存在 CHIP,28 名患者存在 CH。存在 CMD(n=19)的病例与无 CMD(n=158)的对照组进行了比较。病例组年龄为 56±9 岁,女性占 68%,CHIP(27%;=0.028)和 CH(42%;=0.001)的发生率高于对照组。CMD 与主要不良心血管事件的独立风险相关(危险比,3.89[95%CI,1.21-12.56];=0.023),而该风险的 32%是由 CH 介导的。CH 介导的风险约为 CMD 对主要不良心血管事件的直接影响的 0.5 倍。
在人类中,我们观察到患有 CMD 的患者更有可能存在 CHIP,并且 CMD 导致的近三分之一的主要不良心血管事件是由 CH 介导的。